米国のコンパニオンアニマル用心臓医薬品の市場規模、シェア、動向分析レポート：医薬品別、動物タイプ別、適応症別、最終用途別、流通チャネル別、セグメント予測、2025年～2033年

市場規模と動向：

米国のコンパニオンアニマル用心臓医薬品の市場規模は、2024年に7億7,629万米ドルと推計され、2033年には14億9,952万米ドルに達すると予測され、2025年から2033年までのCAGRは7.76%で成長すると予測されます。

市場開拓の主な要因としては、ペットの心臓病罹患率の上昇、ペット医療費の増加、研究開発の増加などが挙げられます。

例えば、Small Door Inc.が発表した記事によると、うっ血性心不全（CHF）は犬に比較的多く、犬全体の約10％、何らかの心臓病を患う老犬の約75％が罹患しています。

コンパニオンアニマルの心臓病罹患率の増加は、獣医心臓病学サービスを拡大する重要な原動力となりつつあります。一般的な獣医療、栄養、ライフスタイルの改善によりペットが長生きするようになると、心臓血管系疾患などの慢性的な加齢関連疾患を発症する可能性が高くなります。獣医師は、弁膜症、心筋症、不整脈など、専門的な知識と治療が必要な疾患を診断することが増えています。

獣医循環器学は近年大きな進歩を遂げ、動物の心臓疾患の診断と治療方法を一変させました。診断ツール、手術手技、治療法における革新は、治療の精度を高め、ペットの治療成績と生活の質を向上させています。例えば、2025年4月、オーバーン大学獣医学部は、僧帽弁上狭窄症の子猫ハッシュブラウンに画期的な手術を行いました。このハイブリッド・バルーン弁形成術は、このような小さくて幼い患者に対する世界初の手術であり、専門家による共同作業が行われました。

革新的な治療法の台頭と、ペットの心臓の健康の重要性に対する意識の高まりが、獣医心臓病学業界の成長を後押ししています。ペットの飼い主は、かつては人間にしかできなかった延命治療が可能であることを認識し、動物に専門的な治療を求めるようになっています。その結果、高度な獣医循環器学サービスの需要は拡大し、現代獣医医療の重要な構成要素としての地位がさらに確固たるものになると予想されます。

たとえば、2024年6月、インド農業研究評議会は、2022年7月から2023年9月までの14ヵ月間にわたって、全身疾患の既往歴のある435頭の犬の心臓不整脈の発生率を調査した研究を発表しました。この評価は不整脈の発生を調べることを目的としたもので、114頭（26.21％）の犬が心房細動（30.70％）、STセグメントコービング、洞停止（各9.65％）、STセグメント上昇（各8.77％）など様々なタイプを示しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国のコンパニオンアニマル用心臓医薬品市場の変動動向と展望

• 市場系統の見通し
  • 親市場
  • 補助市場
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場機会分析
  • 市場課題分析
• 米国のコンパニオンアニマル用心臓医薬品市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 規制の枠組み
  • 価格分析
  • ペット飼育者の人口統計
  • 主要国別、主要種別のペット推定個体数（2024年）

第4章 米国のコンパニオンアニマル用心臓医薬品市場：医薬品推定・動向分析

• セグメントダッシュボード
• 米国のコンパニオンアニマル用心臓医薬品市場：医薬品変動分析
• 米国のコンパニオンアニマル用心臓医薬品市場規模と動向分析（医薬品別、2021年～2033年）
• ピモベンダン
• スピロノラクトンと塩酸ベナゼプリル
• その他

第5章 米国のコンパニオンアニマル用心臓医薬品市場：動物タイプ別推定・動向分析

• セグメントダッシュボード
• 米国のコンパニオンアニマル用心臓医薬品市場：動物タイプ別変動分析
• 米国のコンパニオンアニマル用心臓医薬品市場規模と動向分析（動物タイプ別、2021年～2033年）
• 犬
• 猫
• 馬
• その他

第6章 米国のコンパニオンアニマル用心臓医薬品市場：適応症推定・動向分析

• セグメントダッシュボード
• 米国のコンパニオンアニマル用心臓医薬品市場：適応症変動分析
• 米国のコンパニオンアニマル用心臓医薬品市場規模と動向分析（適応症別、2021年～2033年）
• うっ血性心不全
• 心筋疾患
• 不整脈
• その他

第7章 米国のコンパニオンアニマル用心臓医薬品市場：最終用途推定・動向分析

• セグメントダッシュボード
• 米国のコンパニオンアニマル用心臓医薬品市場：最終用途変動分析
• 米国のコンパニオンアニマル用心臓医薬品市場規模と動向分析（最終用途別、2021年～2033年）
  • 動物病院・クリニック
  • その他

第8章 米国のコンパニオンアニマル用心臓医薬品市場：流通チャネル推定・動向分析

• セグメントダッシュボード
• 米国のコンパニオンアニマル用心臓医薬品市場：流通チャネル変動分析
• 米国のコンパニオンアニマル用心臓医薬品市場規模と動向分析（流通チャネル別、2021年～2033年）
  • 病院/クリニック薬局
  • 小売り
  • eコマース

第9章 競合情勢

• 市場参入企業の分類
• 企業の市況分析/ヒープマップ分析
• 企業プロファイル
  • Zoetis
  • Boehringer Ingelheim International Gmbh
  • Elanco
  • Merck &Co., Inc.
  • Dechra Pharmaceuticals PLC
  • Ceva Sante Animale
  • Phibro Animal Health Corporation
  • Virbac
  • Bimeda Corporate
  • Biogenesis Bago
• 戦略マッピング
  • 合併と買収
  • パートナーシップとコラボレーション
  • アプリケーションの起動
  • その他
• その他の主要人物一覧

List of Tables

• Table 1 List of secondary sources
• Table 2 U.S Companion Animal Cardiac Pharmaceuticals Market, by Pharmaceuticals, 2021 - 2033 (USD Million)
• Table 3 U.S Companion Animal Cardiac Pharmaceuticals Market, by Animal type, 2021 - 2033 (USD Million)
• Table 4 U.S Companion Animal Cardiac Pharmaceuticals Market, by Indication, 2021 - 2033 (USD Million)
• Table 5 U.S Companion Animal Cardiac Pharmaceuticals Market, by End Use, 2021 - 2033 (USD Million)
• Table 6 U.S Companion Animal Cardiac Pharmaceuticals Market, by Distribution Channel, 2021 - 2033 (USD Million)
• Table 7 Company Overview
• Table 8 Product Benchmarking
• Table 9 Financial Performance
• Table 10 Strategic Initiatives

List of Figures

• Fig. 1 Market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. Companion Animal Cardiac Pharmaceuticals Market revenue, 2021 - 2033 (USD Million)
• Fig. 10 U.S. Companion Animal Cardiac Pharmaceuticals Market snapshot
• Fig. 11 U.S. Companion Animal Cardiac Pharmaceuticals Market driver impact
• Fig. 12 U.S. Companion Animal Cardiac Pharmaceuticals Market restraint impact
• Fig. 13 U.S. Companion Animal Cardiac Pharmaceuticals key takeaways (USD Million)
• Fig. 14 U.S. Companion Animal Cardiac Pharmaceuticals Market: pharmaceuticals movement analysis
• Fig. 15 Pimobendan market, 2021 - 2033 (USD Million)
• Fig. 16 Spironolactone and benazepril hydrochloride market, 2021 - 2033 (USD Million)
• Fig. 17 Others market, 2021 - 2033 (USD Million)
• Fig. 18 U.S. Companion Animal Cardiac Pharmaceuticals animal type key takeaways (USD Million)
• Fig. 19 U.S. Companion Animal Cardiac Pharmaceuticals Market: animal Type movement analysis
• Fig. 20 Dogs market, 2021 - 2033 (USD Million)
• Fig. 21 Cats market, 2021 - 2033 (USD Million)
• Fig. 22 Horses market, 2021 - 2033 (USD Million)
• Fig. 23 Others market, 2021 - 2033 (USD Million)
• Fig. 24 U.S. Companion Animal Cardiac Pharmaceuticals Market Indication key takeaways (USD Million)
• Fig. 25 U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication movement analysis
• Fig. 26 Congestive Heart Failure market, 2021 - 2033 (USD Million)
• Fig. 27 Myocardial (Heart Muscle) Disease market, 2021 - 2033 (USD Million)
• Fig. 28 Arrhythmias market, 2021 - 2033 (USD Million)
• Fig. 29 Others market, 2021 - 2033 (USD Million)
• Fig. 30 U.S. Companion Animal Cardiac Pharmaceuticals Market End Use key takeaways (USD Million)
• Fig. 31 U.S. Companion Animal Cardiac Pharmaceuticals Market: End use movement analysis
• Fig. 32 Veterinary Hospitals & Clinics market, 2021 - 2033 (USD Million)
• Fig. 33 Others market, 2021 - 2033 (USD Million)
• Fig. 34 U.S. Companion Animal Cardiac Pharmaceuticals Market Distribution Channel key takeaways (USD Million)
• Fig. 35 U.S. Companion Animal Cardiac Pharmaceuticals Market: Distribution Channel movement analysis
• Fig. 36 Hospital/ Clinic Pharmacy market, 2021 - 2033 (USD Million)
• Fig. 37 Retail market, 2021 - 2033 (USD Million)
• Fig. 38 E-Commerce market, 2021 - 2033 (USD Million)
• Fig. 39 Market participant categorization

Market Size & Trends:

The U.S. companion animal cardiac pharmaceuticals market size was estimated at USD 776.29 million in 2024 and is projected reach USD 1,499.52 million by 2033, growing at a CAGR of 7.76% from 2025 to 2033. The key factors responsible for driving the market growth include the rising incidence of heart diseases in pets, increasing pet health expenditure, and increasing research and development.

For instance, according to an article published by Small Door Inc., Congestive heart failure (CHF) is relatively prevalent in dogs, affecting around 10% of the overall canine population and as many as 75% of older dogs who suffer from some form of heart disease.

The growing incidence of heart disease among companion animals is becoming a key driver in expanding veterinary cardiology services. As pets live longer due to general veterinary care, nutrition, and lifestyle improvements, they are more likely to develop chronic age-related conditions such as cardiovascular diseases. Veterinarians are increasingly diagnosing conditions such as valvular diseases, cardiomyopathies, and arrhythmias, which require specialized knowledge and treatment.

Veterinary cardiology has witnessed significant advancements in recent years, transforming how heart conditions in animals are diagnosed and treated. Innovations in diagnostic tools, surgical techniques, and therapeutic options are enhancing the precision of care and improving the outcomes and quality of life for pets. For instance, in April 2025, Auburn University's College of Veterinary Medicine performed a groundbreaking surgery on Hashbrown, a kitten with supravalvular mitral stenosis. This hybrid balloon valvuloplasty, a first-of-its-kind procedure for such a small and young patient, involved a collaborative effort by professionals.

The rise in innovative treatments and the increasing awareness of the importance of heart health in pets is driving growth in the veterinary cardiology industry. Pet owners increasingly seek specialized care for their animals, recognizing the availability of life-extending treatments that were once only accessible to humans. As a result, the demand for advanced veterinary cardiology services is expected to grow, further solidifying its place as a crucial component of modern veterinary medicine.

For example, in June 2024, the Indian Council for Agricultural Research published a study examining the incidence of cardiac arrhythmias in 435 dogs with a history of generalized diseases over 14 months from July 2022 to September 2023. The assessment was aimed to determine the occurrence of arrhythmias and found that 114 dogs (26.21%) displayed various types, including atrial fibrillation (30.70%), ST-segment coving, sinus arrest (9.65% each), and ST-segment elevation (8.77% each).

U.S. Companion Animal Cardiac Pharmaceuticals Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. companion animal cardiac pharmaceuticals market report based on pharmaceuticals, animal type, indication, end use, and distribution channel.

• Pharmaceuticals Outlook (Revenue, USD Million, 2021 - 2033)
• Pimobendan
• Spironolactone and Benazepril Hydrochloride
• Others
• Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
• Dogs
• Cats
• Horses
• Others
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Congestive Heart Failure
• Myocardial (Heart Muscle) Disease
• Arrhythmias
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals & Clinics
• Others
• Distribution Channel (Revenue, USD Million, 2021 - 2033)
• Hospital/ Clinic Pharmacy
• Retail
• E-Commerce

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Companion Animal Cardiac Pharmaceuticals Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of heart diseases in pets
    • 3.2.1.2. Advancements in veterinary medicine
    • 3.2.1.3. Increasing research & development
    • 3.2.1.4. Increasing adoption of pet insurance
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of treatment
    • 3.2.2.2. Lack of skilled professionals
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
  • 3.3.3. Regulatory Framework
  • 3.3.4. Pricing Analysis
  • 3.3.5. Pet ownership Demographics
  • 3.3.6. Estimated pet Population by key countries, key species, 2024

Chapter 4. U.S. Companion Animal Cardiac Pharmaceuticals Market: Pharmaceuticals Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Pharmaceuticals Movement Analysis
• 4.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by pharmaceuticals, 2021 to 2033 (USD Million)
• 4.4. Pimobendan
  • 4.4.1. Pimobendan Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Spironolactone and benazepril hydrochloride
  • 4.5.1. Spironolactone and benazepril hydrochloride Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Companion Animal Cardiac Pharmaceuticals Market: Animal Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Animal type Movement Analysis
• 5.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by Animal type, 2021 to 2033 (USD Million)
• 5.4. Dogs
  • 5.4.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Cats
  • 5.5.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Horses
  • 5.6.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: Indication Movement Analysis
• 6.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 6.4. Congestive Heart Failure
  • 6.4.1. Congestive Heart Failure Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Myocardial (Heart Muscle) Disease
  • 6.5.1. Myocardial (Heart Muscle) Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Arrhythmias
  • 6.6.1. Arrhythmias Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Companion Animal Cardiac Pharmaceuticals Market: By End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: By End Use Movement Analysis
• 7.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by end use, 2021 to 2033 (USD Million)
  • 7.3.1. Veterinary Hospitals & Clinics
    • 7.3.1.1. Veterinary Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Others
    • 7.3.2.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Companion Animal Cardiac Pharmaceuticals Market: By Distribution Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. U.S. Companion Animal Cardiac Pharmaceuticals Market: By Distribution Channel Movement Analysis
• 8.3. U.S. Companion Animal Cardiac Pharmaceuticals Market Size & Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 8.3.1. Hospital/ Clinic Pharmacy
    • 8.3.1.1. Hospital/ Clinic Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. Retail
    • 8.3.2.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. E-Commerce
    • 8.3.3.1. E-Commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Position Analysis/ Heap Map Analysis
• 9.3. Company Profiles
  • 9.3.1. Zoetis
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Boehringer Ingelheim International Gmbh
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Elanco
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Merck & Co., Inc.
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Dechra Pharmaceuticals PLC
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Ceva Sante Animale
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Phibro Animal Health Corporation
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Virbac
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Bimeda Corporate
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Biogenesis Bago
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives
• 9.4. Strategy Mapping
  • 9.4.1. Mergers & Acquisitions
  • 9.4.2. Partnerships & Collaborations
  • 9.4.3. Application launch
  • 9.4.4. Others
• 9.5. List of other key players